Theravance Biopharma downgraded by Leerink Partners with a new price target

8/6/24 8:00:45 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Leerink Partners downgraded Theravance Biopharma from Outperform to Market Perform and set a new price target of $10.00 from $15.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TBPH

Date	Price Target	Rating	Analyst
8/6/2024	$15.00 → $10.00	Outperform → Market Perform	Leerink Partners
4/12/2024	$21.00	Buy	BTIG Research
1/8/2024		Outperform → In-line	Evercore ISI
5/23/2022	$12.00	Outperform	SVB Leerink
3/2/2022	$10.00 → $11.00	Underweight	Morgan Stanley
2/24/2022	$8.00 → $12.00	Buy	HC Wainwright & Co.
11/5/2021	$7.00 → $12.00	Underweight → Neutral	JP Morgan
9/16/2021	$14.00 → $10.00	Underweight	Morgan Stanley